EUVIMEDEUVIMED entdecken
Systematische ÜbersichtUmbrella Review

TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review

R F Alves, C Hilário, N B Ferreira, M Cascais, J P Ramos, M Vieira, A Aguiar, R Duarte

The International Journal of Tuberculosis and Lung Disease · 01.06.2026 · 30 (6) · 244-254

DOI: 10.5588/ijtld.25.0518 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 01.06.2026. Verfasst von R F Alves und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Tuberculosis, Biological Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

Biological therapies and Janus kinase (JAK) inhibitors have revolutionised the management of immune-mediated and oncologic diseases, but concerns remain regarding their potential to increase TB risk.





OBJECTIVE

To systematically synthesise evidence from previous systematic reviews on the risk of TB disease associated with different biological classes and JAK inhibitors.





METHODS

Following Preferred Reporting Items for Overviews of Reviews guidelines, we conducted an umbrella review of systematic reviews and meta-analyses, registered in PROSPERO (CRD42024497515). Twenty-five reviews met the inclusion criteria. Data were extracted on TB incidence, risk estimates, type, and time to onset. Risk of bias was assessed using ROBIS.





RESULTS

Anti-TNF monoclonal antibodies (infliximab, adalimumab) were consistently associated with the highest TB risk (odds ratio commonly 3–5), with greater proportions of disseminated/extra-pulmonary disease compared to etanercept. Combination immunosuppression further increased risk. IL-6, IL-17, and IL-23 inhibitors showed low TB reactivation rates under screening and prophylaxis protocols. JAK inhibitors (notably tofacitinib) conferred geographically variable risk, higher in intermediate/high-burden countries. Immune checkpoint inhibitors, especially PD-1/PD-L1 agents, were linked to TB incidence far above background rates.





CONCLUSION

TB risk varies markedly across biologic and targeted agents. Risk-based TB infection screening and tailored prophylaxis beyond anti-TNF therapy are warranted, particularly in endemic regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsTuberculosisBiological FactorsHumans

Substanzen

Janus Kinase InhibitorsBiological Factors

Autor:innen und Institutionen

  • Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
  • Serviço de Pneumologia, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal.
  • Serviço de Pneumologia, Unidade Local de Saúde do Tâmega e Sousa, Porto, Portugal.
  • Serviço de Pneumologia, Unidade Local de Saúde de São João, Porto, Portugal.
  • Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal;, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Porto, Porto, Portugal.
  • Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal;, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Porto, Porto, Portugal;, Instituto Nacional de Sa…

Zitieren

APA

Alves, R. F., Hilário, C., Ferreira, N. B., Cascais, M., Ramos, J. P., Vieira, M., Aguiar, A., & Duarte, R. (2026). TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review. The International Journal of Tuberculosis and Lung Disease, 30(6), 244-254. https://doi.org/10.5588/ijtld.25.0518

Vancouver

Alves RF, Hilário C, Ferreira NB, Cascais M, Ramos JP, Vieira M, et al. TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review. The International Journal of Tuberculosis and Lung Disease. 2026;30(6):244-254. doi:10.5588/ijtld.25.0518

BibTeX
@article{Alves2026,
  author = {Alves, R F and Hilário, C and Ferreira, N B and Cascais, M and Ramos, J P and Vieira, M and Aguiar, A and Duarte, R},
  title = {TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {244--254},
  doi = {10.5588/ijtld.25.0518}
}
Kostenlos starten →